PRCM
UTHR icon

Pine River Capital Management’s United Therapeutics UTHR Stock Holding History

Pine River Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-4,100
Closed -$457K – 584
2016
Q1 		$457K Buy
4,100
+1,447
+55% +$183K 0.01% 577
2015
Q4 		$415K Sell
2,653
-1,147
-30% -$167K 0.01% 561
2015
Q3 		$499K Buy
3,800
+900
+31% +$144K 0.01% 537
2015
Q2 		$504K Buy
+2,900
New +$522K 0.01% 509

Other funds holding UTHR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Pine River Capital Management's UTHR Position: Q2 2016 in Review

Pine River Capital Management sold out of United Therapeutics (UTHR) in Q2 2016, closing a stake of 4,100 shares — an estimated $457K sold.

Pine River Capital Management first reported a position in UTHR in Q2 2015 and held it in 4 quarters. The position peaked at $504K in Q2 2015. 384 funds tracked by Wall St. Rank hold UTHR as of Q2 2016.

  • Pine River Capital Management reported no remaining United Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Pine River Capital Management sold 4,100 United Therapeutics shares in Q2 2016, an estimated $457K.
  • Pine River Capital Management first reported a position in United Therapeutics in Q2 2015 and held it in 4 quarters.
  • Pine River Capital Management's United Therapeutics position peaked at $504K in Q2 2015.
  • 384 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2016.

Based on Pine River Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.